A Clinical Study of GRC 8200 in Type 2 Diabetes Mellitus
Status:
Unknown status
Trial end date:
2009-10-01
Target enrollment:
Participant gender:
Summary
The study is aimed at evaluating efficacy and safety of GRC 8200 in type 2 diabetes mellitus
patients.
The study involves six weeks of wash out period and two weeks run in period for patients
currently on mono-therapy and a two week run in period only for drug naïve patients.
This is a placebo controlled study. One of the five treatment arms is placebo. The duration
of treatment is 12 weeks.